Análisis de la acción Ginkgo Bioworks Holdings Inc (DNA)DNAGinkgo Bioworks Holdings Inc

Ginkgo Bioworks Holdings, Inc. offers biological research and development (R&D) services on its platform and autonomous laboratory to enable its customers to bring their products to market. The Company sells tools and biological R&D services across a range of industries to government and commercial customers. Its in-house autonomous lab is available as Cloud Lab through its Datapoints and Solutions contract research services. Its single segment, namely cell engineering, provides tools and biological R&D services across a range of industries. Its cell engineering customers work with biology to discover and manufacture new products across industries such as medicine, agriculture, industrial biotechnology and government. It provides R&D services spanning genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics. It provides a suite of microservices for product developers across industries that support bioengineers with protein engineering. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Ginkgo Bioworks is not a good buy right now due to significant financial losses and negative analyst sentiment. The current price is $6.96, with a recent downgrade from TD Cowen lowering the price target to $9 and BTIG to $5, indicating a lack of confidence in future growth. Additionally, the company reported a Q2 GAAP EPS of -0.92, reflecting ongoing challenges in revenue growth and a projected cash burn of $125 million to $150 million for 2026, which raises concerns about its financial stability.

2 analysts cover DNA: 0 rate it Buy, 0 Hold and 2 Sell. The average price target is 12.00.